RAPID: a Comparison Study of a Novel Ultrasound Device of Automated Congenital Heart Imaging
Launched by UNIVERSITY OF MINNESOTA · Feb 19, 2024
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
The RAPID clinical trial is studying a new ultrasound device designed to take quick and easy images of the heart in children with congenital heart disease. This device, called RAPID, is portable and can capture a heart image in less than one minute by being placed on the child's chest. It uses safe ultrasound technology that is suitable for patients of all ages and sizes. The images taken with RAPID will be compared to those taken with standard imaging methods to see how well they work together.
To participate in this trial, children under one year old who are patients at Masonic Children's Hospital or the Masonic Children's Heart Center clinic and are scheduled for a routine heart procedure might be eligible. However, children who have open chest surgery, are on a heart-lung machine (ECMO), or are considered medically unstable by their healthcare team cannot join the study. Participants can expect to have their heart images taken quickly and securely, with all personal information kept private. The goal is to improve heart imaging for children, making the process easier and safer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \<1 years old
- • Be a patient at Masonic Children's Hospital or Masonic Children's Heart Center clinic undergoing PCU
- Exclusion Criteria:
- • Open Chest
- • On ECMO
- • Deemed medically unstable by care team
- • Cardiology, ICU, hospitalist or bedside nurse concerns
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Gwenyth Fischer, MD
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported